Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04101045 · ClinicalTrials.gov registry record · NA
Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT04101045: Clinical Trial NA study, sponsored by Yale University.
NCT04101045 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04101045, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.
Primary Outcome
% Fractional hepatic DNL
Interventions
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2022-03-30 |
| Phase | NA |
Why NCT04101045 stopped before completion
NCT04101045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Oral Glucose Tolerance Test is the first listed.
NCT04101045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04101045 about?
NCT04101045 is a clinical study titled "Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes". The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fra...
What is the current status of trial NCT04101045?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2019-11-21. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04101045?
The interventions under investigation include: Oral Glucose Tolerance Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04101045?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04101045's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI